Dr. Enrique Grande: How Clinical Practice Has Been Changed by Clinical Trials in the Last 10 Years
Dr. Enrique Grande, MD, PhD, Msc, is the Director of the Medical Oncology Program and Clinical Research lead at the MD Anderson Cancer Center Madrid.
In this presentation recorded for INCA in 2022, Dr. Grande gives a snapshot of NET research, how neuroendocrine cancer clinical trials change clinical practice, as well as outlines potentially practice-changing trials.
Highlights of the presentation:
- “PROMID TRIAL was first with SSA’s demonstrating delayed tumor growth. Prior to this, SSA’s only given to control symptoms so it was a major breakthrough to learn that SSA’s could control tumor growth for quite some time”
- “2011 was the next big breakthrough for treatments to postpone and delay the growth of PNETS in G1 and G2 tumors”
- “Gallium PET Scans allowed us to better identify tumor cells and their activity”
- “TELESTAR trial gave us tumor growth control and quality of life improvement”
- “We need better drugs to control the symptoms and the quality of life. It is important to live longer but it is also important to live better. Sometimes researchers are forgetting about this and that is why we need the patient’s input”
Dr. Enrique Grande Bio
Dr. Enrique Grande, MD, PhD, Msc, is the Director of the Medical Oncology Program and Clinical Research Lead at the MD Anderson Cancer Center Madrid. Dr. Grande is focused on research on genitourinary and endocrine tumors and actively contributes to the development of the Translational Research and Early Drug Development Unit. Dr. Grande was awarded his PhD for a pharmacokinetic and pharmacodynamic study of tyrosine kinase inhibitors in liver metabolism, and he holds a master’s degree in molecular biology of cancer from the Spanish National Cancer Research Centre (CNIO). Published author of more than 200 manuscripts in peer-reviewed journals, Dr. Grande is also the founder of the Spanish Group of Research on Orphan and Uncommon Tumors (GETHI).